Piezo1 activation on microglial cells exacerbates demyelination in sepsis by influencing the CCL25/GRP78 pathway

Di Xie1, Yanli Ma2, Chengjin Gao1

  • 1Department of Emergency, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Yangpu District, 200092 Shanghai, China.

PubMed
Abstract

Insights

The protein Piezo1 drives cognitive impairment in sepsis-associated encephalopathy (SAE) by activating microglia and causing oligodendrocyte demyelination. Targeting Piezo1 offers a potential therapeutic strategy for SAE-induced cognitive dysfunction.

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • Sepsis-associated encephalopathy (SAE) involves microglial activation and neuroinflammation, contributing to cognitive deficits.
  • The protein Piezo1 is recognized as a key regulator of neuroinflammation, but its specific role in SAE-related microglial function remains unclear.

Purpose of the Study:

  • To investigate the role of Piezo1 in microglial cells within the context of sepsis-associated encephalopathy (SAE).

Main Methods:

  • Establishment of a mouse model of SAE using cecal ligation and puncture (CLP).
  • Assessment of cognitive function and motor activity using Morris water maze tests.
  • Proteomic and Mendelian randomization analyses to identify SAE-related pathways.
  • Evaluation of inflammatory factors, microglial status, and oligodendrocyte development via immunofluorescence and flow cytometry.
  • Assessment of axonal myelination and Piezo1's effect on oligodendrocyte ferroptosis using electron microscopy and western blot analysis.

Main Results:

  • Bioinformatics analysis identified CCL25 as significantly involved in SAE-induced cognitive impairment.
  • SAE activates microglia, leading to CCL25 release, subsequent oligodendrocyte demyelination, ferroptosis, and disrupted hippocampal connectivity.
  • Genetic knockout of Piezo1 ameliorated these SAE-induced changes, and Piezo1 inhibition reduced inflammatory mediators (CCL25, IL-18) by targeting the p38 pathway and the CCL25/GPR78 axis, preventing oligodendrocyte ferroptosis.

Conclusions:

  • Piezo1 plays a critical role in microglial activation and oligodendrocyte demyelination in SAE models, leading to cognitive impairment.
  • Targeting Piezo1 presents a promising therapeutic avenue for mitigating cognitive dysfunction associated with SAE.